MX2020008422A - Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos. - Google Patents
Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos.Info
- Publication number
- MX2020008422A MX2020008422A MX2020008422A MX2020008422A MX2020008422A MX 2020008422 A MX2020008422 A MX 2020008422A MX 2020008422 A MX2020008422 A MX 2020008422A MX 2020008422 A MX2020008422 A MX 2020008422A MX 2020008422 A MX2020008422 A MX 2020008422A
- Authority
- MX
- Mexico
- Prior art keywords
- preparing
- same
- steroid derivative
- regulators
- sub
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/0025—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Abstract
La presente invención se refiere a reguladores de derivados de esteroides, a un método para prepararlos, y a sus usos. Específicamente, la presente invención se refiere a un compuesto de fórmula (I), un método de preparación para el mismo, una composición farmacéutica que contiene el compuesto y los usos del mismo como regulador del receptor GABA A para tratar la depresión, la convulsión, la enfermedad de Parkinson y enfermedades del sistema nervioso, en donde los sustituyentes de la fórmula (I) son como se definen en la descripción. (ver fórmula I).
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810141153 | 2018-02-11 | ||
CN201810180543 | 2018-03-05 | ||
CN201810491114 | 2018-05-21 | ||
CN201810771964 | 2018-07-13 | ||
CN201811408081 | 2018-11-23 | ||
PCT/CN2019/074134 WO2019154257A1 (zh) | 2018-02-11 | 2019-01-31 | 一种甾族类衍生物调节剂及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008422A true MX2020008422A (es) | 2020-09-21 |
Family
ID=67548159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008422A MX2020008422A (es) | 2018-02-11 | 2019-01-31 | Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210139530A1 (es) |
EP (1) | EP3750908A4 (es) |
JP (2) | JP7438956B2 (es) |
KR (1) | KR20200120661A (es) |
CN (2) | CN114805462A (es) |
AU (1) | AU2019218177B2 (es) |
BR (1) | BR112020016269A2 (es) |
CA (1) | CA3090724A1 (es) |
MX (1) | MX2020008422A (es) |
TW (1) | TW201934125A (es) |
WO (1) | WO2019154257A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA51568A (fr) | 2018-01-12 | 2021-04-21 | Sage Therapeutics Inc | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central |
CA3115805A1 (en) | 2018-10-12 | 2020-04-16 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
CN113383004A (zh) | 2018-12-05 | 2021-09-10 | 萨奇治疗股份有限公司 | 神经活性类固醇及其使用方法 |
WO2020135454A1 (zh) * | 2018-12-26 | 2020-07-02 | 张家口华健致远生物科技有限公司 | 一类类固醇化合物及其用途 |
CN116059215A (zh) * | 2019-01-08 | 2023-05-05 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
JOP20210293A1 (ar) | 2019-05-31 | 2023-01-30 | Sage Therapeutics Inc | ستيرويدات ذات فعالية عصبية وتركيبات منها |
US20230257415A1 (en) * | 2019-06-27 | 2023-08-17 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
JP2022543576A (ja) * | 2019-08-07 | 2022-10-13 | 上▲海▼翰森生物医▲薬▼科技有限公司 | ステロイド誘導体調節因子の塩及び結晶形態 |
PE20221911A1 (es) | 2020-03-25 | 2022-12-23 | Sage Therapeutics Inc | Uso de agentes para el tratamiento de condiciones respiratorias |
KR20230124916A (ko) * | 2020-11-25 | 2023-08-28 | 세이지 테라퓨틱스, 인크. | Cns 장애를 치료하기 위한 조성물 및 방법 |
CN113968886B (zh) * | 2021-11-15 | 2022-12-13 | 湖南科瑞生物制药股份有限公司 | 一种17-甲酸甾体化合物的制备方法 |
CN114933624B (zh) * | 2022-05-24 | 2024-02-20 | 大连理工大学 | 一种天然产物(+)-毛地黄毒苷配基的人工合成方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2453823C2 (de) * | 1974-11-11 | 1984-08-09 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11β,17α-Dihydroxy-15α,16α-methylen-1,4-pregnadien-3,20-dion |
AU609927B2 (en) * | 1987-08-25 | 1991-05-09 | Kelvin W. Gee | Compositions and methods for alleviating stress, anxiety and seizure activity |
US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
GB9213835D0 (en) * | 1992-06-30 | 1992-08-12 | Smithkline Beecham Corp | Compounds |
FR2718138B1 (fr) * | 1994-04-01 | 1996-04-26 | Roussel Uclaf | Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant. |
WO1995028413A1 (en) * | 1994-04-15 | 1995-10-26 | Smithkline Beecham Corporation | 17β-SUBSTITUTED 3-CARBOXY STEROIDS THAT INHIBIT 5-α-REDUCTASE |
UA57706C2 (uk) * | 1995-06-06 | 2003-07-15 | Косенсіз, Інк | Нейроактивні стероїди ряду андростанів та прегнанів, фармацевтична композиція і спосіб лікування (варіанти) |
BR0308355A (pt) | 2002-03-13 | 2005-01-25 | Merck & Co Inc | Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto |
EP2736919A4 (en) * | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
US20150291654A1 (en) * | 2011-10-14 | 2015-10-15 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
EP3909966A1 (en) * | 2013-04-17 | 2021-11-17 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy |
US20160068563A1 (en) * | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
EP2986624B1 (en) * | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids for methods of treatment |
WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
PT3488852T (pt) | 2013-08-23 | 2021-02-03 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
WO2015180679A1 (en) * | 2014-05-29 | 2015-12-03 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
NZ731095A (en) | 2014-10-16 | 2023-12-22 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
WO2016084790A1 (ja) * | 2014-11-25 | 2016-06-02 | 第一三共株式会社 | ヒドロナフトキノリン誘導体 |
JP7065825B2 (ja) * | 2016-07-11 | 2022-05-12 | セージ セラピューティクス, インコーポレイテッド | C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法 |
-
2019
- 2019-01-31 CN CN202210401606.0A patent/CN114805462A/zh active Pending
- 2019-01-31 MX MX2020008422A patent/MX2020008422A/es unknown
- 2019-01-31 US US16/969,133 patent/US20210139530A1/en active Pending
- 2019-01-31 JP JP2020542730A patent/JP7438956B2/ja active Active
- 2019-01-31 KR KR1020207025423A patent/KR20200120661A/ko not_active Application Discontinuation
- 2019-01-31 BR BR112020016269-8A patent/BR112020016269A2/pt unknown
- 2019-01-31 AU AU2019218177A patent/AU2019218177B2/en active Active
- 2019-01-31 WO PCT/CN2019/074134 patent/WO2019154257A1/zh unknown
- 2019-01-31 CN CN201980001355.3A patent/CN110709409B/zh active Active
- 2019-01-31 CA CA3090724A patent/CA3090724A1/en active Pending
- 2019-01-31 EP EP19750850.0A patent/EP3750908A4/en active Pending
- 2019-02-11 TW TW108104455A patent/TW201934125A/zh unknown
-
2024
- 2024-02-07 JP JP2024017080A patent/JP2024045458A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110709409B (zh) | 2022-05-31 |
CA3090724A1 (en) | 2019-08-15 |
WO2019154257A1 (zh) | 2019-08-15 |
US20210139530A1 (en) | 2021-05-13 |
EP3750908A4 (en) | 2022-07-27 |
BR112020016269A2 (pt) | 2020-12-15 |
TW201934125A (zh) | 2019-09-01 |
JP2024045458A (ja) | 2024-04-02 |
AU2019218177B2 (en) | 2024-02-01 |
RU2020126096A (ru) | 2022-03-11 |
KR20200120661A (ko) | 2020-10-21 |
AU2019218177A1 (en) | 2020-09-17 |
EP3750908A1 (en) | 2020-12-16 |
JP7438956B2 (ja) | 2024-02-27 |
CN114656514A (zh) | 2022-06-24 |
CN110709409A (zh) | 2020-01-17 |
JP2021513532A (ja) | 2021-05-27 |
CN114805462A (zh) | 2022-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008422A (es) | Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos. | |
MX2020008182A (es) | Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos. | |
ZA202102544B (en) | Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof | |
MX2021006283A (es) | Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos. | |
MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
MX2010002538A (es) | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas. | |
MY152078A (en) | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones | |
EA200801934A1 (ru) | 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2 | |
UA109220C2 (uk) | Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів | |
EA200901160A1 (ru) | Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она | |
EA200901159A1 (ru) | Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она | |
WO2012042539A3 (en) | 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders | |
MX2022001784A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos. | |
TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
ATE549311T1 (de) | Amino-propanolderivative als modulatoren des sphingosin-1-phosphat-rezeptors | |
MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
MX2022008091A (es) | Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
ZA202206266B (en) | Pd-l1 antagonist compound | |
NZ766972A (en) | Compounds having s1p5 receptor agonistic activity | |
PH12020500572A1 (en) | Substituted alkynylene compounds as anticancer agents | |
MX2022004473A (es) | Modificador de un derivado de anillo de cuatro miembros, metodo de preparacion y aplicacion del mismo. | |
WO2022247920A9 (zh) | 喹啉胺类化合物、其制备方法及其在医药上的应用 | |
MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
GEP20156227B (en) | Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same | |
JOP20180057A1 (ar) | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |